222 related articles for article (PubMed ID: 11147511)
1. Practical issues with COMT inhibitors in Parkinson's disease.
Waters C
Neurology; 2000; 55(11 Suppl 4):S57-9; discussion S60-4. PubMed ID: 11147511
[TBL] [Abstract][Full Text] [Related]
2. Issues important for rational COMT inhibition.
Dingemanse J
Neurology; 2000; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
[TBL] [Abstract][Full Text] [Related]
3. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease.
Schapira AH; Obeso JA; Olanow CW
Neurology; 2000; 55(11 Suppl 4):S65-8; discussion S69-71. PubMed ID: 11147512
[TBL] [Abstract][Full Text] [Related]
4. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Kaakkola S
Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
[TBL] [Abstract][Full Text] [Related]
5. Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials.
Kieburtz K; Hubble J
Neurology; 2000; 55(11 Suppl 4):S42-5; discussion S46-50. PubMed ID: 11147509
[TBL] [Abstract][Full Text] [Related]
6. COMT inhibition in the treatment of Parkinson's disease.
Ruottinen HM; Rinne UK
J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
[TBL] [Abstract][Full Text] [Related]
7. COMT inhibitors and liver toxicity.
Watkins P
Neurology; 2000; 55(11 Suppl 4):S51-2; discussion S53-6. PubMed ID: 11147510
[TBL] [Abstract][Full Text] [Related]
8. New options for treatment of Parkinson's disease.
LeWitt PA
Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871
[TBL] [Abstract][Full Text] [Related]
9. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.
Benabou R; Waters C
Expert Opin Drug Saf; 2003 May; 2(3):263-7. PubMed ID: 12904105
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of COMT inhibitors.
Brooks DJ
Neurology; 2004 Jan; 62(1 Suppl 1):S39-46. PubMed ID: 14718679
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
Arnold G; Kupsch A
Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007
[TBL] [Abstract][Full Text] [Related]
12. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
[TBL] [Abstract][Full Text] [Related]
13. Extending levodopa action: COMT inhibition.
Martínez-Martín P; O'Brien CF
Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
[TBL] [Abstract][Full Text] [Related]
14. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
Onofrj M; Thomas A; Iacono D; Di Iorio A; Bonanni L
Eur Neurol; 2001; 46(1):11-6. PubMed ID: 11455177
[TBL] [Abstract][Full Text] [Related]
15. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.
Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736
[TBL] [Abstract][Full Text] [Related]
16. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.
Factor SA; Molho ES; Feustel PJ; Brown DL; Evans SM
Clin Neuropharmacol; 2001; 24(5):295-9. PubMed ID: 11586115
[TBL] [Abstract][Full Text] [Related]
17. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
18. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
[TBL] [Abstract][Full Text] [Related]
19. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
Korlipara LV; Cooper JM; Schapira AH
Neuropharmacology; 2004 Mar; 46(4):562-9. PubMed ID: 14975680
[TBL] [Abstract][Full Text] [Related]
20. Clinical advantages of COMT inhibition with entacapone - a review.
Gordin A; Kaakkola S; Teräväinen H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
